Positive outcomes with novel episcleral brachytherapy device for wet AMD
A minimally invasive retrobulbar episcleral brachytherapy device (SMD-I device) (Salutaris Medical Devices) has shown considerable promise in the treatment of a small cohort of exudative AMD patients, according to Kamaljit Balaggan MRCOphth, PhD.
Dr Balaggan reported the feasibility and tolerability of the SMD-I investigational treatment for wet AMD using a single dose of episcleral brachytherapy in conjunction with intraocular anti-VEGF injections.
He noted the strong rationale for using radiation in exudative AMD, taking account of factors such as the radiosensitivity of the proliferating endothelial cells, the reduction in inflammatory and fibrotic processes, and the occlusion of aberrant vessels including vessels with pericyte maturation. Combining radiation treatment and anti-VEGF drugs may reduce the burden of anti-VEGF treatment, increase the proportion of treatment responders and preserve best-corrected visual acuity.
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.